FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891926485> ?p ?o ?g. }

• W2891926485 endingPage "288" @default.
• W2891926485 startingPage "276" @default.
• W2891926485 abstract "Background: Cancer is the second leading cause of mortality worldwide after heart diseases, and lung cancer is the topmost cause of all cancer-related deaths in both sexes. Dihydropyrimidinones (DHPMs) are medicinally important class of molecules with diverse pharmacological activities including anticancer activity. The present study focuses on the molecular hybridization of novel Benzopyran with Dihydropyrimidinone and evaluation of the resulting hybrids for cancer cell proliferation, migration and tumor growth. Methods: We have synthesized a focused library of dihydropyrimidinone benzopyran hybrids (compounds 1-11) by joining the aromatic as well as pyran portions of the benzopyran core with dihydropyrimidinone. All the synthesized hybrid molecules were evaluated for their cytotoxic activities against a panel of four human cancer cell lines of diverse tissue origin, viz: A549 (lung carcinoma), MCF7 (mammary gland adenocarcinoma), HCT-116 (colorectal carcinoma), and PANC-1 (pancreatic duct carcinoma) with the help of MTT cell viability assay. A structure-activity relationship was made on the basis of IC50 values of different hybrids. Effect on cell proliferation was examined through colony formation assay, reactive oxygen species generation and mitochondrial membrane potential studies. Wound healing assays and cell scattering assays were employed to check the effect on cell migration. Western blotting experiments were performed to find out the molecular mechanism of action and anti-tumor studies were carried out to evaluate the in vivo efficacy of the selected lead molecule. Results: Two types of novel hybrids were synthesized efficiently from benzopyran aldehydes, ethylacetoacetate and urea under heteropolyacid catalysis. Compound 3 was found to be the most potent hybrid among the synthesized compounds with consistent cytotoxic activities against four human cancer cell lines (IC50 values: 0.139 - 2.32 μM). Compound 3 strongly inhibited proliferation abilities of A549 cells in colony formation assay. Compound 3 exerted oxidative stress-mediated mitochondrial dysfunction, in which mitochondrial reactive oxygen species (ROS) generation as a mechanism of its anti-proliferative effects was analysed. Further, the molecule abrogated migration and cell scattering properties of aggressive PANC-1 cells. Mechanistic studies revealed that compound 3 modulated NF-kB expression and its downstream oncogenic proteins involved in cancer cell proliferation and invasion. Finally, compound 3 confirmed its in vivo anti-tumor efficacy; there observed 41.87% tumor growth inhibition at a dose of 30 mg/kg/body weight against a mouse model of Ehrlich solid tumor. Conclusion: Our study unravels a potential anticancer lead (compound 3) from DHPMs that have opened up new research avenues for the development of promising anticancer therapeutic agents." @default.
• W2891926485 created "2018-09-27" @default.
• W2891926485 creator A5009745758 @default.
• W2891926485 creator A5016480596 @default.
• W2891926485 creator A5032072999 @default.
• W2891926485 creator A5039123387 @default.
• W2891926485 creator A5043352981 @default.
• W2891926485 creator A5043736464 @default.
• W2891926485 creator A5067075931 @default.
• W2891926485 creator A5072915164 @default.
• W2891926485 creator A5085389581 @default.
• W2891926485 date "2019-05-31" @default.
• W2891926485 modified "2023-09-26" @default.
• W2891926485 title "Synthesis and Investigation of the Role of Benzopyran Dihydropyrimidinone Hybrids in Cell Proliferation, Migration and Tumor Growth" @default.
• W2891926485 cites W1888783223 @default.
• W2891926485 cites W1964847767 @default.
• W2891926485 cites W1989372473 @default.
• W2891926485 cites W2031949901 @default.
• W2891926485 cites W2035756271 @default.
• W2891926485 cites W2041585461 @default.
• W2891926485 cites W2042023148 @default.
• W2891926485 cites W2043118554 @default.
• W2891926485 cites W2045824232 @default.
• W2891926485 cites W2048326611 @default.
• W2891926485 cites W2053036921 @default.
• W2891926485 cites W2055886738 @default.
• W2891926485 cites W2060728660 @default.
• W2891926485 cites W2061546615 @default.
• W2891926485 cites W2066745496 @default.
• W2891926485 cites W2073582287 @default.
• W2891926485 cites W2079825767 @default.
• W2891926485 cites W2093921289 @default.
• W2891926485 cites W2094507356 @default.
• W2891926485 cites W2094974725 @default.
• W2891926485 cites W2095332815 @default.
• W2891926485 cites W2101018764 @default.
• W2891926485 cites W2116892749 @default.
• W2891926485 cites W2117582353 @default.
• W2891926485 cites W2117692326 @default.
• W2891926485 cites W2122341467 @default.
• W2891926485 cites W2127457669 @default.
• W2891926485 cites W2138503145 @default.
• W2891926485 cites W2142194481 @default.
• W2891926485 cites W2164195423 @default.
• W2891926485 cites W2165200432 @default.
• W2891926485 cites W2166110966 @default.
• W2891926485 cites W2299463172 @default.
• W2891926485 cites W2315810573 @default.
• W2891926485 cites W2325984664 @default.
• W2891926485 cites W2329905280 @default.
• W2891926485 cites W796527232 @default.
• W2891926485 doi "https://doi.org/10.2174/1871520618666180903101422" @default.
• W2891926485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30179143" @default.
• W2891926485 hasPublicationYear "2019" @default.
• W2891926485 type Work @default.
• W2891926485 sameAs 2891926485 @default.
• W2891926485 citedByCount "5" @default.
• W2891926485 countsByYear W28919264852019 @default.
• W2891926485 countsByYear W28919264852022 @default.
• W2891926485 countsByYear W28919264852023 @default.
• W2891926485 crossrefType "journal-article" @default.
• W2891926485 hasAuthorship W2891926485A5009745758 @default.
• W2891926485 hasAuthorship W2891926485A5016480596 @default.
• W2891926485 hasAuthorship W2891926485A5032072999 @default.
• W2891926485 hasAuthorship W2891926485A5039123387 @default.
• W2891926485 hasAuthorship W2891926485A5043352981 @default.
• W2891926485 hasAuthorship W2891926485A5043736464 @default.
• W2891926485 hasAuthorship W2891926485A5067075931 @default.
• W2891926485 hasAuthorship W2891926485A5072915164 @default.
• W2891926485 hasAuthorship W2891926485A5085389581 @default.
• W2891926485 hasConcept C1491633281 @default.
• W2891926485 hasConcept C150903083 @default.
• W2891926485 hasConcept C185592680 @default.
• W2891926485 hasConcept C207001950 @default.
• W2891926485 hasConcept C2776286485 @default.
• W2891926485 hasConcept C2780783641 @default.
• W2891926485 hasConcept C502942594 @default.
• W2891926485 hasConcept C53227056 @default.
• W2891926485 hasConcept C55493867 @default.
• W2891926485 hasConcept C62112901 @default.
• W2891926485 hasConcept C71240020 @default.
• W2891926485 hasConcept C86803240 @default.
• W2891926485 hasConcept C98274493 @default.
• W2891926485 hasConceptScore W2891926485C1491633281 @default.
• W2891926485 hasConceptScore W2891926485C150903083 @default.
• W2891926485 hasConceptScore W2891926485C185592680 @default.
• W2891926485 hasConceptScore W2891926485C207001950 @default.
• W2891926485 hasConceptScore W2891926485C2776286485 @default.
• W2891926485 hasConceptScore W2891926485C2780783641 @default.
• W2891926485 hasConceptScore W2891926485C502942594 @default.
• W2891926485 hasConceptScore W2891926485C53227056 @default.
• W2891926485 hasConceptScore W2891926485C55493867 @default.
• W2891926485 hasConceptScore W2891926485C62112901 @default.
• W2891926485 hasConceptScore W2891926485C71240020 @default.
• W2891926485 hasConceptScore W2891926485C86803240 @default.
• W2891926485 hasConceptScore W2891926485C98274493 @default.
• W2891926485 hasFunder F4320320718 @default.
• W2891926485 hasIssue "2" @default.

• next